-
A short exposure to a specific combination of two growth factors may be all it takes to stimulate the growth of new blood vessels that persist indefinitely, a new study suggests.
-
As expected, the Cypher drug-eluting coronary stent from Johnson & Johnson (New Brunswick, New Jersey) subsidiary Cordis (Miami Lakes, Florida) is the first to market in the U.S. after receiving FDA approval late last month.
-
CHICAGO, Illinois The U.S. introduction of drug-eluting stents, made possible by the FDAs late-April approval of the Cypher stent from Johnson & Johnsons (New Brunswick, New Jersey) Cordis (Miami Lakes, Florida) unit, will open a new chapter in the history of interventional cardiology and drive significant changes in medical practice as well as in market share for suppliers.
-
-
S. Lewis Meyer, PhD, has been named president and CEO of Lipid Sciences (Pleasanton, California). He will continue to serve as a director, a position he has held since July 2002. Meyer was president and CEO of Imatron until its acquisition by GE Medical Systems in December 2001.
-
A call to action to increase the awareness, detection and treatment of peripheral arterial disease (PAD) among healthcare professionals was published last month in the Archives of Internal Medicine.
-
Cardiac Science (Irvine, California), a manufacturer of public access defibrillators, said it is now working in conjunction with the American Red Cross (Washington) national organization and local Red Cross chapters across the country to make Powerheart automated external defibrillators (AEDs) available to businesses, government facilities and individuals in their communities.
-
Edwards Lifesciences (Irvine, California) reported completion early this month of a 20-year follow-up on the effectiveness and durability of its leading aortic pericardial tissue heart valve.
-
CryoCath Technologies (Montreal, Quebec), a developer of cryotherapy products to treat cardiovascular disease, reached an agreement with Endocare (Irvine, California) to acquire the exclusive and permanent global rights to SurgiFrost, a surgical probe system to ablate cardiac arrhythmias.
-
The congenital Marfan syndrome afflicts some 200,000 people in the U.S. Worldwide, the incidence is one in 10,000, or about 700,000 of the planets population.
